390 related articles for article (PubMed ID: 29038265)
1. Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.
Xu J; Tasneen R; Peloquin CA; Almeida DV; Li SY; Barnes-Boyle K; Lu Y; Nuermberger E
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038265
[TBL] [Abstract][Full Text] [Related]
2. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.
Almeida D; Ioerger T; Tyagi S; Li SY; Mdluli K; Andries K; Grosset J; Sacchettini J; Nuermberger E
Antimicrob Agents Chemother; 2016 Aug; 60(8):4590-9. PubMed ID: 27185800
[TBL] [Abstract][Full Text] [Related]
3. Acquired resistance of Mycobacterium tuberculosis to bedaquiline.
Andries K; Villellas C; Coeck N; Thys K; Gevers T; Vranckx L; Lounis N; de Jong BC; Koul A
PLoS One; 2014; 9(7):e102135. PubMed ID: 25010492
[TBL] [Abstract][Full Text] [Related]
4. Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.
Gupta S; Tyagi S; Bishai WR
Antimicrob Agents Chemother; 2015 Jan; 59(1):673-6. PubMed ID: 25331694
[TBL] [Abstract][Full Text] [Related]
5. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K
J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270
[TBL] [Abstract][Full Text] [Related]
6. Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.
Chen C; Gardete S; Jansen RS; Shetty A; Dick T; Rhee KY; Dartois V
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463541
[No Abstract] [Full Text] [Related]
7. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis.
Gupta S; Cohen KA; Winglee K; Maiga M; Diarra B; Bishai WR
Antimicrob Agents Chemother; 2014; 58(1):574-6. PubMed ID: 24126586
[TBL] [Abstract][Full Text] [Related]
8. Clofazimine Exposure
Ismail N; Peters RPH; Ismail NA; Omar SV
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642938
[TBL] [Abstract][Full Text] [Related]
9. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
[TBL] [Abstract][Full Text] [Related]
10. High Prevalence of Bedaquiline Resistance in Treatment-Naive Tuberculosis Patients and Verapamil Effectiveness.
Ghajavand H; Kargarpour Kamakoli M; Khanipour S; Pourazar Dizaji S; Masoumi M; Rahimi Jamnani F; Fateh A; Siadat SD; Vaziri F
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602521
[TBL] [Abstract][Full Text] [Related]
11. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis.
Sonnenkalb L; Carter JJ; Spitaleri A; Iqbal Z; Hunt M; Malone KM; Utpatel C; Cirillo DM; Rodrigues C; Nilgiriwala KS; Fowler PW; Merker M; Niemann S;
Lancet Microbe; 2023 May; 4(5):e358-e368. PubMed ID: 37003285
[TBL] [Abstract][Full Text] [Related]
12. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis.
Nimmo C; Millard J; van Dorp L; Brien K; Moodley S; Wolf A; Grant AD; Padayatchi N; Pym AS; Balloux F; O'Donnell M
Lancet Microbe; 2020 Aug; 1(4):e165-e174. PubMed ID: 32803174
[TBL] [Abstract][Full Text] [Related]
13. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
14. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.
Ghodousi A; Rizvi AH; Baloch AQ; Ghafoor A; Khanzada FM; Qadir M; Borroni E; Trovato A; Tahseen S; Cirillo DM
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262765
[TBL] [Abstract][Full Text] [Related]
15. Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis.
Nimmo C; Ortiz AT; Tan CCS; Pang J; Acman M; Millard J; Padayatchi N; Grant AD; O'Donnell M; Pym A; Brynildsrud OB; Eldholm V; Grandjean L; Didelot X; Balloux F; van Dorp L
Genome Med; 2024 Feb; 16(1):34. PubMed ID: 38374151
[TBL] [Abstract][Full Text] [Related]
16. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
[TBL] [Abstract][Full Text] [Related]
17. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.
Hartkoorn RC; Uplekar S; Cole ST
Antimicrob Agents Chemother; 2014 May; 58(5):2979-81. PubMed ID: 24590481
[TBL] [Abstract][Full Text] [Related]
18. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.
Tasneen R; Williams K; Amoabeng O; Minkowski A; Mdluli KE; Upton AM; Nuermberger EL
Antimicrob Agents Chemother; 2015 Jan; 59(1):129-35. PubMed ID: 25331697
[TBL] [Abstract][Full Text] [Related]
19. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
[TBL] [Abstract][Full Text] [Related]
20. Emergence of Canonical and Noncanonical Genomic Variants following
Ismail N; Dippenaar A; Warren RM; Peters RPH; Omar SV
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0136822. PubMed ID: 36892309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
